Cartesian Therapeutics Goodwill

The latest goodwill for RNAC is $48M as of March 2026. That compares with $48M in the prior-year period — up 0.0% year over year. Investors often review this figure alongside Cartesian Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, RNAC's goodwill moved from $48M to $48M — essentially flat versus a year earlier. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Cartesian Therapeutics's operating scale or balance-sheet position.

A goodwill figure of $48M for RNAC is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting RNAC's goodwill ($48M), review year-over-year change from $48M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Cartesian Therapeutics's goodwill against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.